Napredna pretraga

Pregled bibliografske jedinice broj: 706386

Improved early diagnosis of Alzheimer's disease by combination of cerebrospinal fluid biomarkers


Babić, Mirjana; Vogrinc, Željka; Dejanović, Nenad; Borovečki, Fran; Hof, Patrick R.; Šimić, Goran
Improved early diagnosis of Alzheimer's disease by combination of cerebrospinal fluid biomarkers // 9th FENS Forum of Neuroscience / FENS (ur.).
Milano: FENS, 2014. str. 100-100 (poster, međunarodna recenzija, sažetak, znanstveni)


Naslov
Improved early diagnosis of Alzheimer's disease by combination of cerebrospinal fluid biomarkers

Autori
Babić, Mirjana ; Vogrinc, Željka ; Dejanović, Nenad ; Borovečki, Fran ; Hof, Patrick R. ; Šimić, Goran

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
9th FENS Forum of Neuroscience / FENS - Milano : FENS, 2014, 100-100

Skup
9th FENS Forum of Neuroscience

Mjesto i datum
Milano, Italija, 05-09.07.2014.

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Mild cognitive impairment; Alzheimer's disease; cerebrospinal fluid biomarkers

Sažetak
Alzheimer's disease (AD) is the leading primary cause of dementia. Mild cognitive impairment (MCI) is a syndrome characterized by cognitive impairment without dementia. About 12% of MCI patients however have an initial stage of AD. There is an urgent need for novel CSF biomarkers to improve the early diagnosis of AD. Visinin-like protein-1 (VILIP-1), a neuron- specific intracellular calcium sensor protein, is a novel promising biomarker of AD. VILIP-1 was previously identified as a marker of neuronal injury. Thus, the objective of this study was to assess whether combination of cerebrospinal fluid VILIP-1 and tau protein phosphorylated at threonine 181 (p-tau 181) could improve early diagnosis of AD. The concentration of VILIP-1 and p-tau 181 was determined using ELISA kits in the CSF of 60 patients with probable AD, 30 MCI patients, and 14 healthy controls (HC). Levels of VILIP-1 were significantly higher in the group of AD patients than in MCI patients (p = 0.001). ROC curve analysis showed that VILIP-1 could differentiate AD patients from HC with a sensitivity and specificity of 86.7% and 57.1%, respectively, while VILIP-1/p-tau 181 ratio reached 75% sensitivity and 71.4% specificity. About 50% of MCI patients had VILIP-1 and p-tau 181 levels higher than the cut-off (assessed by ROC curve analysis). Even though a follow-up period of at minimum 5 years is necessary to determine whether MCI high-risk patients will convert to AD, the combination of VILIP-1 and p-tau 181 could considerably improve AD detection in the preclinical stages of the disease.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti, Psihologija



POVEZANOST RADA


Projekt / tema
108-1081870-1942 - Fosforilacija tau proteina u razvitku i Alzheimerovoj bolesti (Goran Šimić, )
HRZZ-09/16 - Otkrivanje i praćenje bioloških biljega radi rane terapijske intervencije u Alzheimerovoj bolesti (Goran Šimić, )

Ustanove
Medicinski fakultet, Zagreb